A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving durvalumab in combination with tremelimumab
This pharmacovigilance study describes the safety profile of durvalumab plus tremelimumab in HCC. The findings may inform clinical monitoring strategies, though prospective studies are warranted for confirmation.
Authors
- Zhaoshuo Chen
- Mingzuo Wang
- Cheng Yang (ORCID: https://orcid.org/0000-0003-4367-7962)
- Xue Zhong (ORCID: https://orcid.org/0000-0003-0813-7506)
- Mingji Zhang (ORCID: https://orcid.org/0000-0001-9531-5862)
- Yi Yao (ORCID: https://orcid.org/0000-0003-2601-9423)
- Fan Zhang (ORCID: https://orcid.org/0009-0001-0721-340X)
Institutions
- Fujian Medical University (CN)
- Fujian Provincial Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-29
- DOI
- https://doi.org/10.3389/fimmu.2025.1657398
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64